Free Trial
→ The Iran War Isn’t Chaos. It’s Strategy. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$18.63
+0.1%		$26.09
$18.39
▼
$30.96
$3.20B0.881.73 million shs310 shs
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$9.99
+1.0%		$13.32
$8.94
▼
$25.77
$844.74M1.371.36 million shs14,718 shs
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$27.00
+0.6%		$35.83
$24.51
▼
$42.49
$3.34BN/A746,263 shs677 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$34.26
-0.5%		$52.45
$34.00
▼
$72.66
$3.30B0.61.39 million shs7,268 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-4.07%-5.65%-33.09%-28.16%-7.18%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-5.99%+0.20%-29.71%-57.75%-4.90%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-7.25%-6.96%-27.20%-10.23%+2,684,999,900.00%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-3.88%-5.88%-41.31%-49.17%-13.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$18.63
+0.1%		$26.09
$18.39
▼
$30.96
$3.20B0.881.73 million shs310 shs
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$9.99
+1.0%		$13.32
$8.94
▼
$25.77
$844.74M1.371.36 million shs14,718 shs
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$27.00
+0.6%		$35.83
$24.51
▼
$42.49
$3.34BN/A746,263 shs677 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$34.26
-0.5%		$52.45
$34.00
▼
$72.66
$3.30B0.61.39 million shs7,268 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-4.07%-5.65%-33.09%-28.16%-7.18%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-5.99%+0.20%-29.71%-57.75%-4.90%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-7.25%-6.96%-27.20%-10.23%+2,684,999,900.00%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-3.88%-5.88%-41.31%-49.17%-13.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.72
Moderate Buy$31.3468.23% Upside
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
2.75
Moderate Buy$26.67166.99% Upside
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
2.71
Moderate Buy$41.6754.32% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.87
Moderate Buy$70.14104.73% Upside

Current Analyst Ratings Breakdown

Latest GLUE, XENE, PBLS, and ACAD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/13/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Neutral$49.00 ➝ $23.00
10/11/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$17.00 ➝ $19.00
10/11/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold
10/8/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$37.00 ➝ $36.00
10/6/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$73.00
10/5/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$25.00
10/5/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/2/2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D+) ➝ Sell (D)
10/2/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/1/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$25.00
10/1/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$25.00
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B3.00$0.85 per share21.88$7.25 per share2.57
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$123.67M6.89N/AN/A$3.58 per share2.79
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M441.60N/AN/A$7.53 per share4.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.228.3619.01N/A33.42%9.03%6.79%11/4/2026 (Estimated)
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$38.63M-$1.76N/AN/AN/A-560.85%-43.31%-27.59%11/5/2026 (Estimated)
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-$145.89M-$2.13N/AN/AN/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$345.91M-$4.74N/AN/AN/AN/A-43.98%-41.72%11/2/2026 (Estimated)

Latest GLUE, XENE, PBLS, and ACAD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.2396N/AN/AN/A$33.87 millionN/A
11/4/2026Q3 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.1992N/AN/AN/A$332.42 millionN/A
11/2/2026Q3 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.13N/AN/AN/A$1.33 millionN/A
8/13/2026Q2 2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-$0.16-$2.32-$2.16-$2.32N/A$0.15 million
8/6/2026Q2 2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.3805-$0.43-$0.0495-$0.43$12.91 million$8.97 million
8/6/2026Q2 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.16-$1.11+$0.05-$1.11$1.67 millionN/A
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.0682$0.18+$0.1119$0.18$296.55 million$308.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/AN/AN/AN/AN/A
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.39
3.30
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/A
10.58
10.58
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A
17.91
17.91
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
21.01
21.02

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
79.96%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
6.40%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
798172.31 million127.16 millionOptionable
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
17385.31 million79.85 millionOptionable
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
145123.53 millionN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
36496.67 million93.85 millionOptionable

Recent News About These Companies

Bank of America Securities Sticks to Their Buy Rating for Xenon (XENE)
October 13 at 9:03 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XENE-Q/pressreleases/6740944/bank-of-america-securities-sticks-to-their-buy-rating-for-xenon-xene/
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month Low - Here's Why
October 13 at 1:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xenon-pharmaceuticals-nasdaq-xene-hits-new-12-month-low-heres-why-2026-10-13/
Xenon Pharmaceuticals (NASDAQ:XENE) Downgraded by Wall Street Zen to "Strong Sell"
October 11 at 1:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106676
Xenon Pharmaceuticals (NASDAQ:XENE) Cut to "Strong Sell" at Wall Street Zen
October 11 at 1:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-xenon-pharmaceuticals-nasdaq-xene-cut-to-strong-sell-at-wall-street-zen-2026-10-11/
Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-xenon-pharmaceuticals-xene-getting-231010016.html
Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline
October 9, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/xenon-pharmaceuticals-xene-stock-may-141401053.html
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376617/1453/en/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors.html
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year Low - Here's Why
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xenon-pharmaceuticals-nasdaq-xene-sets-new-1-year-low-heres-why-2026-10-06/
Xenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at Guggenheim
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31091629
Guggenheim Reaffirms "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-guggenheim-reaffirms-buy-rating-for-xenon-pharmaceuticals-nasdaq-xene-2026-10-06/
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026
October 5, 2026  |  biospace.comB
Xenon CFO buys 15,000 shares
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084186
Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Ian Mortimer Purchases 30,000 Shares
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082446
Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Thomas Patrick Kelly Buys 15,000 Shares
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082444
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Moderate Buy" from Brokerages
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081952
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Moderate Buy" from Brokerages
October 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-xenon-pharmaceuticals-inc-nasdaq-xene-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-10-03/
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Climb 5.2% After Insider Buying Activity
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081757
Wall Street Zen Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Sell"
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081512
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Lifted to "Sell" by Wall Street Zen
October 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-xenon-pharmaceuticals-nasdaq-xene-stock-lifted-to-sell-by-wall-street-zen-2026-10-03/
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  financialpost.comF
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3374010/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$18.63 +0.01 (+0.05%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Monte Rosa Therapeutics stock logo

Monte Rosa Therapeutics NASDAQ:GLUE

$9.99 +0.10 (+0.99%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Parabilis Medicines stock logo

Parabilis Medicines NASDAQ:PBLS

$27.00 +0.15 (+0.56%)
As of 08:55 AM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$34.26 -0.16 (-0.46%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas